Current Psychiatry Reports

, 16:527 | Cite as

Proceed with Caution: Off-label Ketamine Treatment for Major Depressive Disorder

  • Dominic SistiEmail author
  • Andrea G. Segal
  • Michael E. Thase
Mood Disorders (JF Greden, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Mood Disorders


Ketamine offers a promising new option for the treatment of depression, but its increasing off-label use is ethically and clinically inappropriate at the moment.


Ketamine Depression Ethics Consent Safety 


Compliance with Ethics Guidelines

Conflict of Interest

Dominic Sisti and Andrea G. Segal declare that they have no conflict of interest.

Michael Thase reports personal fees from Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Gerson Lehman Group, GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Merck and Co., Neuronetics, Inc., Ortho-McNeil Pharmaceuticals, Pfizer, Roche, Shire US, Inc., Sunovion Pharmaceuticals, Inc., and Takeda. Dr. Thase also has received grants and personal fees from Eli Lilly & Co., Forest Laboratories, and Otsuka as well as royalties from the American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc., and Peloton Advantage.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4. doi: 10.1016/S0006-3223(99)00230-9.CrossRefPubMedGoogle Scholar
  2. 2.
    Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959–64.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.••
    Stix G. From club to clinic: physicians push off-label ketamine as rapid depression treatment, part 1. Scientific American. 2013. This article provides a thorough overview of the current issues and controversies involved in using ketamine as a treatment for major depressive disorder.Google Scholar
  4. 4.
    Department of Justice. Intelligence bulletin: ketamine. 2004(2004-L0424-007).Google Scholar
  5. 5.•
    Murrough JW, Wan L-B, Iacoviello B, Collins KA, Solon C, Glicksberg B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology. 2014;23(3):481–8. doi: 10.1007/s00213-013-3255-x. This study examined neurocognitive performance in depressed patients and found that patients who responded to ketamine 24 h following treatment had poorer baseline neurocognitive performance than nonresponders.CrossRefGoogle Scholar
  6. 6.
    Carter LP, Kleykamp BA, Griffiths RR, Mintzer MZ. Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology. 2013;226(1):53–63.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Loo CK, Katalinic N, Garfield JBB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 2012;142(1–3):233–40. doi: 10.1016/j.jad.2012.04.032.CrossRefPubMedGoogle Scholar
  8. 8.
    McDaniel WW, Sahota AK, Vyas BV, Laguerta N, Hategan L, Oswald J. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J ECT. 2006;22(2):103–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105(1):121–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Reier CE. Ketamine—“dissociative agent” or hallucinogen? N Engl J Med. 1971;284(14):791–2.PubMedGoogle Scholar
  11. 11.
    Green SM, Krauss B. The semantics of ketamine. Ann Emerg Med. 2000;36(5):480–2.CrossRefPubMedGoogle Scholar
  12. 12.
    Muetzelfeldt L, Kamboj S, Rees H, Taylor J, Morgan C, Curran H. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95(3):219–29.CrossRefPubMedGoogle Scholar
  13. 13.
    Jeste DV, Saks E. Decisional capacity in mental illness and substance use disorders: empirical database and policy implications. Behav Sci Law. 2006;24(4):607–28.CrossRefPubMedGoogle Scholar
  14. 14.
    Appelbaum PS, Grisso T, Frank E, O’Donnell S, Kupfer DJ. Competence of depressed patients for consent to research. Am J Psychiatr. 1999;156(9):1380–4.PubMedGoogle Scholar
  15. 15.
    Depression Recovery Centers. Prospective Patients. 2014.
  16. 16.
    Lorant V, Deliège D, Eaton W, Robert A, Philippot P, Ansseau M. Socioeconomic inequalities in depression: a meta-analysis. Am J Epidemiol. 2003;157(2):98–112.CrossRefPubMedGoogle Scholar
  17. 17.••
    Schatzberg AF. A word to the wise about ketamine. Am J Psychiatr. 2014;171(3):262–4. A review of concerns surrounding the administration of ketamine for major depressive disorder concludes with the argument that until more is known about its effects and risks, “clinicians should be wary about embarking on a slippery ketamine slope.”.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Dominic Sisti
    • 1
    Email author
  • Andrea G. Segal
    • 1
  • Michael E. Thase
    • 2
  1. 1.Department of Medical Ethics & Health Policy, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Psychiatry, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations